Table 2. Correlation between high/low GADD45A expression and clinic pathological factors in 419 breast cancer tissues.
| Characteristics | GADD45A expression | Total | χ2 | P | |
|---|---|---|---|---|---|
| High (%) | Low (%) | ||||
| Age at diagnosis (years) | |||||
| ≤50 | 119 (70.0) | 51 (30.0) | 170 | ||
| >50 | 184 (73.9) | 65 (26.1) | 249 | 0.766 | 0.382 |
| TNM stage | |||||
| I | 77 (68.1) | 36 (31.9) | 113 | ||
| II | 168 (72.1) | 65 (27.9) | 233 | ||
| III | 58 (79.5) | 15 (20.5) | 73 | 2.846 | 0.241 |
| Pathology type | |||||
| IDC | 269 (73.7) | 96 (26.3) | 365 | ||
| non-IDC | 34 (63.0) | 20 (37.0) | 54 | 2.708 | 0.100 |
| Histological grade | |||||
| I–II | 200 (68.7) | 91 (31.3) | 291 | ||
| III | 103 (80.5) | 25 (19.5) | 128 | 6.120 | 0.013 |
| Molecular subtype | |||||
| Luminal A | 40 (54.1) | 34 (45.9) | 74 | ||
| Luminal B | 157 (76.2) | 49 (23.8) | 206 | ||
| HER2-enriched | 56 (80.0) | 14 (20.0) | 70 | ||
| Triple negative | 50 (72.5) | 19 (27.5) | 69 | 23.584 | <0.001 |
| ER | |||||
| positive | 172 (68.5) | 79 (31.5) | 251 | ||
| negative | 131 (78.0) | 37 (22.0) | 168 | 4.489 | 0.034 |
| PR | |||||
| positive | 163 (70.3) | 69 (29.7) | 232 | ||
| negative | 140 (74.9) | 47 (25.1) | 187 | 1.098 | 0.295 |
| HER2 | |||||
| positive | 134 (75.7) | 43 (24.3) | 177 | ||
| negative | 169 (69.8) | 73 (30.2) | 242 | 1.760 | 0.185 |
| Ki-67 | |||||
| ≥20% | 207 (83.1) | 42 (16.7) | 249 | ||
| <20% | 96 (56.2) | 74 (43.5) | 170 | 35.871 | <0.001 |
Notes.
- IDC
- invasive ductal carcinoma
- ER
- estrogen receptor
- PR
- progesterone receptor
- HER2
- human epidermal growth factor receptor 2